Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors, p.5, 2003. ,
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1072, issue.2-3, 1991. ,
DOI : 10.1016/0304-419X(91)90011-9
Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling., Journal of Clinical Investigation, vol.97, issue.3, 1996. ,
DOI : 10.1172/JCI118480
Synthesis of sulfoxides by the hydrogen peroxide induced oxidation of sulfides catalysed by iron tetrakis(pentafluorophenyl)porphyrin: scope and chemoselectivity, 2004. ,
Prostaglandins and other lipid mediators in Alzheimer???s disease, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, pp.68-69, 2002. ,
DOI : 10.1016/S0090-6980(02)00031-X
A new series of selective and orally potent 5-lipoxygenase inhibitors ,
A quantum chemical study of the synthesis of prostaglandin G 2 by the cyclooxygenase active site, 2003. ,
The unique profile of nabumetone, 1992. ,
Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family., Proceedings of the National Academy of Sciences, vol.89, issue.19, 1992. ,
DOI : 10.1073/pnas.89.19.9044
Human prostate cancer risk factors, Cancer, vol.17, issue.S10, pp.2371-2490, 2004. ,
DOI : 10.1002/cncr.20408
A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors, Inflammation Research, vol.271, issue.2, pp.68-74, 1996. ,
DOI : 10.1007/BF02265118
Modulators of Leukotriene Biosynthesis and Receptor Activation, Journal of Medicinal Chemistry, vol.39, issue.14, 1996. ,
DOI : 10.1021/jm960088k
The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo, Oncogene, vol.19, issue.20, pp.2404-2412, 2000. ,
DOI : 10.1038/sj.onc.1203571
Carcinogenic nitrogen compounds. Part XXXIX. A new synthesis of ?-carbolines and of 2, p.10, 1964. ,
Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs, European Journal of Medicinal Chemistry, vol.38, issue.7-8, 2003. ,
DOI : 10.1016/S0223-5234(03)00115-6
250. Synthesis of some 5-substituted-2-methyltryptamines and their N-mono- and -di-alkyl derivatives, Journal of the Chemical Society (Resumed), 1965. ,
DOI : 10.1039/jr9650001424
Mechanism of the irreversible deactivation of arachidonate 5, p.6, 1984. ,
? ? ? ?-carbolines et analogues, Nouvelles synthèses et étude des relations structure-activité cytotoxique et antitumorale, 1996. ,
A new series of selective and orally potent 5-lipoxygenase inhibitor ,
Cyclooxygenase inhibitors ??? current status and future prospects, European Journal of Medicinal Chemistry, vol.36, issue.2, 2001. ,
DOI : 10.1016/S0223-5234(01)01197-7
New trends in dual 5-LOX, 2002. ,
Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2, European Journal of Biochemistry, vol.242, issue.1-2, 1988. ,
DOI : 10.1016/S0010-8545(00)80316-1
Asthma Therapy with Agents Preventing Leukotriene Synthesis or Action, Proceedings of the Association of American Physicians, vol.111, issue.6, 1999. ,
DOI : 10.1016/S0149-2918(97)80092-6
Naphtalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids, 1994. ,
DOI : 10.1021/jm00030a010
Learning the Value of Drugs ??? Is Rofecoxib a Regulatory Success Story?, New England Journal of Medicine, vol.352, issue.13, pp.1285-1287, 2005. ,
DOI : 10.1056/NEJMp048358
Criteria for the identification of non-redox inhibitors of, p.5, 1993. ,
Organometallic chemistry. XII. The thermal decomposition of n-butyllithium, a kinetic study, 1965. ,
Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?11Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclooxygenase; LT, leukotriene; 5-LOX, 5-lipoxygenase; PG, prostaglandin; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsuphonyl)-phenyl-2(5H)-furanone; and DFP, diisopropyl fluorophosphate., Biochemical Pharmacology, vol.62, issue.11, pp.1433-1438, 2001. ,
DOI : 10.1016/S0006-2952(01)00747-X
The coxibs, selective inhibitors of cyclooxygenase-2, 2001. ,
Effect of a new anti-inflammatory drug (oxamethacine) on the prostaglandin biosynthesis, Farmacol, vol.35, pp.498-503, 1980. ,
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology, Science, vol.294, issue.5548, pp.1871-1875, 2001. ,
DOI : 10.1126/science.294.5548.1871
The structures of prostaglandin endoperoxide H synthases-1, p.2, 2002. ,
]carbazole-1-carboxylic Acid (2-(Dimethylamino)ethyl)amide and Their 10- and 11-Methyl Analogues with Improved Antitumor Activity, Journal of Medicinal Chemistry, vol.42, issue.12, 1999. ,
DOI : 10.1021/jm981093m
Leukotriene A 4 hydrolase, Prostaglandins Other Lipid Mediat, pp.68-69, 2002. ,
-yl)benznesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2, p.522 ,
COX-2 inhibitors, The Lancet, vol.353, issue.9149, pp.307-314, 1999. ,
DOI : 10.1016/S0140-6736(98)12154-2
Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors, 1999. ,
Prostaglandins Induce Vascular Endothelial Growth Factor in a Human Monocytic Cell Line and Rat Lungs via cAMP, American Journal of Respiratory Cell and Molecular Biology, vol.17, issue.6, 1997. ,
DOI : 10.1165/ajrcmb.17.6.2888
Computer-assisted drug design, Journal of Medicinal Chemistry, vol.28, issue.9, 1985. ,
DOI : 10.1021/jm00147a001
Manipulation of substituents at nitrogen in tropanes, homotropanes, and dehydro- derivatives, Tetrahedron, vol.54, issue.36, pp.10899-10914, 1998. ,
DOI : 10.1016/S0040-4020(98)00643-7
Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma, 2002. ,
Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal antiinflammatory drugs (NO-AINS) on human urological tumor cell lines, 2005. ,
Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells, Carcinogenesis, vol.22, issue.5, pp.701-707, 2001. ,
DOI : 10.1093/carcin/22.5.701
Inhibitory effects of tryptophan pyrolysis products on human platelet aggregation through inhibition of prostaglandin endoperoxide synthetase, Food and Chemical Toxicology, vol.25, issue.11, 1987. ,
DOI : 10.1016/0278-6915(87)90261-4
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis, The Prostate, vol.194, issue.2, 2005. ,
DOI : 10.1002/pros.20276
Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPAR?) signaling in prostate cancer, 2004. ,
Synthesis of 2-cyano-1,3-dibenzoyl-2,3-dihydrobenzimidazole: a novel Reissert compound from benzimidazole, The Journal of Organic Chemistry, vol.56, issue.2, pp.865-867, 1991. ,
DOI : 10.1021/jo00002a071
Structural and Functional Criteria Reveal a New Nuclear Import Sequence on the 5-Lipoxygenase Protein, Journal of Biological Chemistry, vol.277, issue.41, 2002. ,
DOI : 10.1074/jbc.M206070200
Recent Development in the Field of Dual COX / 5-LOX Inhibitors, Mini-Reviews in Medicinal Chemistry, vol.4, issue.6, 2004. ,
DOI : 10.2174/1389557043403747
Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors, Journal of Medicinal Chemistry, vol.43, issue.15, 2000. ,
DOI : 10.1021/jm000004e
Growth factors involved in prostate carcinogenesis, Frontiers in Bioscience, vol.10, issue.1-3, pp.1355-1367, 2005. ,
DOI : 10.2741/1625
A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells, The Journal of Cell Biology, vol.119, issue.6, 1992. ,
DOI : 10.1083/jcb.119.6.1701
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res, vol.58, pp.409-412, 1998. ,
The effect of 15-Lipoxygenase-1 expression on cancer cells, Current Urology Reports, vol.268, issue.3, 2002. ,
DOI : 10.1007/s11934-002-0066-8
Chemoprevention of Prostate Cancer: Concepts and Strategies, European Urology, vol.35, issue.5-6, 1999. ,
DOI : 10.1159/000019906
Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6, p.14, 1987. ,
??-Carbolines: binding at 5-HT5A serotonin receptors, Bioorganic & Medicinal Chemistry, vol.11, issue.5, 2003. ,
DOI : 10.1016/S0968-0896(02)00527-8
The role of cyclooxygenase-2 in prostate cancer, Urology, vol.58, issue.2, pp.127-131, 2001. ,
DOI : 10.1016/S0090-4295(01)01255-9
Chemoprevention of prostate cancer, 2005. ,
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, vol.384, issue.6610, pp.644-648, 1996. ,
DOI : 10.1038/384644a0
Synthetic studies on condensed-azole derivatives. IV. 1) Synthesis and anti-asthmatic activities of ?-sulfamoylalkyloxyimidazo, p.2, 1996. ,
Synthetic studies on condensed-azole derivatives. V. 1) Synthesis and anti-asthmatic activities of ?-sulfamoylalkyloxy, pp.4-5, 1997. ,
Lewis acid assisted permanganate oxidations, Tetrahedron, vol.58, issue.49, pp.9879-9887, 2002. ,
DOI : 10.1016/S0040-4020(02)01227-9
A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes ,
Some reactions of pyrido, p.3, 1981. ,
Nonsteroidal anti-inflammatory drugs. Mechanisms ans clinical uses, 1994. ,
-Tetrahydro-?-carbolinium salts: novel reactions with thiols, 2004. ,
DOI : 10.1016/j.tetlet.2004.04.078
Biomimetic synthesis of the pentacyclic alkaloid (±)-Nirunine and possible biogenetic rearrangement of a precursor into, 1992. ,
Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate, 2005. ,
Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs, 2001. ,
Recent developments in cyclooxygenase inhibition, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, pp.68-69, 2002. ,
DOI : 10.1016/S0090-6980(02)00027-8
NEUTRALIZING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY INHIBITS FURTHER GROWTH OF ESTABLISHED PROSTATE CANCER AND METASTASES IN A PRE-CLINICAL MODEL, The Journal of Urology, 1999. ,
DOI : 10.1097/00005392-199903000-00071
Influence of body mass index on biochemical outcome after permanent prostate brachytherapy, Urology, vol.65, issue.1, pp.95-100, 2005. ,
DOI : 10.1016/j.urology.2004.08.044
Elaboration d'un modèle de pharmacophore et d'interactions d'inhibiteurs sélectifs de la cyclooxygénase-2, 2004. ,
Distinct functions of COX-1 and COX-2, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, 2002. ,
DOI : 10.1016/S0090-6980(02)00029-1
Risk of cardiovascular events associated with selective COX-2 inhibitors, 2001. ,
Proapoptotic anti-inflammatory drugs, Urology, vol.57, issue.4, pp.73-76, 2001. ,
DOI : 10.1016/S0090-4295(00)00945-6
Liquid chromatographic???mass spectrometric determination of cyclooxygenase metabolites of arachidonic acid in cultured cells, Journal of Chromatography B, vol.785, issue.1, 2003. ,
DOI : 10.1016/S1570-0232(02)00906-6
Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas, Gastroenterology, vol.124, issue.1, pp.57-70, 2003. ,
DOI : 10.1053/gast.2003.50011
Raising the Safety Bar ??? The FDA's Coxib Meeting, New England Journal of Medicine, vol.352, issue.13, 2005. ,
DOI : 10.1056/NEJMp058055
Chemoprevention of intestinal polyposis in the Apc delta716 mouse by rofecoxib, 2001. ,
Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4- nitrophenyl]methanesulphonamide (NS-398) and 5-méthanesulphonamido-6, on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases, pp.4-5, 1995. ,
Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism, Clinical Cancer Research, vol.11, issue.5, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-1877
Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells, International Journal of Cancer, vol.292, issue.2, 2004. ,
DOI : 10.1002/ijc.20245
Formic acid-formaldehyde methylation of amines, The Journal of Organic Chemistry, vol.36, issue.6, 1971. ,
DOI : 10.1021/jo00805a022
Involvement of PI3K/Akt pathway in prostate cancer, 2005. ,
Colocalization of Cytosolic Phospholipase A2, 5-Lipoxygenase, and 5-Lipoxygenase-Activating Protein at the Nuclear Membrane of A23187-Stimulated Human Neutrophils, European Journal of Biochemistry, vol.40, issue.1, 1996. ,
DOI : 10.1006/bbrc.1995.1388
Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE, Progress in Lipid Research, vol.44, issue.2-3, 2005. ,
DOI : 10.1016/j.plipres.2005.04.002
The discovery of rofecoxib, MK 966, Vioxx ®5H)- furanone], an orally active cyclooxygenase-2 inhibitor, pp.4-4, 1999. ,
Is cyclooxygenase-2 the alpha and the omega in cancer?, Journal of Clinical Investigation, vol.105, issue.11, pp.1511-1513, 2000. ,
DOI : 10.1172/JCI10241
Connection between metalation and cross-coupling strategies. A new convergent route to azacarbazoles., Tetrahedron, vol.49, issue.1, pp.49-64, 1993. ,
DOI : 10.1016/S0040-4020(01)80505-6
Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs., Proceedings of the National Academy of Sciences, vol.72, issue.12, 1975. ,
DOI : 10.1073/pnas.72.12.4863
Synthesis and platelet aggregation inhibitory, p.5, 1981. ,
Synthesis of potential selective COX-2 enzyme inhibitors derived from ethyl ester of 2-isothiocyanato-5-phenyl-3-thiophencarboxylic acid, 2003. ,
Oxidation of sulfides to sulfoxides and sulfones with 30% hydrogen peroxide under organic solvent- and halogen-free conditions, Tetrahedron, vol.57, issue.13, pp.2469-2476, 2001. ,
DOI : 10.1016/S0040-4020(01)00068-0
The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2, 1997. ,
Prostate cancer: a dynamic illness with shifting targets, The Lancet Oncology, vol.4, issue.7, pp.407-414, 2003. ,
DOI : 10.1016/S1470-2045(03)01138-0
The enzymology of prostaglandin endoperoxide H synthases-1 and -2, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, p.2, 2002. ,
DOI : 10.1016/S0090-6980(02)00025-4
Intramolecular Hetero Diels???Alder Routes to ??-Carboline Alkaloids, Tetrahedron, vol.56, issue.30, pp.5329-5335, 2000. ,
DOI : 10.1016/S0040-4020(00)00468-3
Valdecoxib and Parecoxib Sodium, Drugs of the Future, vol.26, issue.2, pp.133-140, 2001. ,
DOI : 10.1358/dof.2001.026.02.610299
Compounds affecting the central nervous system. II, pp.4-7, 1966. ,
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis, New England Journal of Medicine, vol.342, issue.26, pp.1946-1952, 2000. ,
DOI : 10.1056/NEJM200006293422603
Synthesis of ?-carbolines and ?-carbolines via intramolecular Diels-Alder reactions of, 1998. ,
Target to apoptosis: A hopeful weapon for prostate cancer, The Prostate, vol.224, issue.4, 1997. ,
DOI : 10.1002/(SICI)1097-0045(19970901)32:4<284::AID-PROS9>3.0.CO;2-J
The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2, Inflammation Research, vol.51, issue.3, pp.135-143, 2002. ,
DOI : 10.1007/PL00000285
Prostanoid receptor subtypes, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, pp.68-69, 2002. ,
DOI : 10.1016/S0090-6980(02)00054-0
Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells, Cell, vol.93, issue.5, pp.705-716, 1998. ,
DOI : 10.1016/S0092-8674(00)81433-6
The Cyclooxygenase Reaction Mechanism, Biochemistry, vol.41, issue.52, pp.15451-15458, 2002. ,
DOI : 10.1021/bi026938h
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs, Nature New Biology, vol.231, issue.25, 1971. ,
DOI : 10.1038/newbio231232a0
Resistance of prostate cancer cell lines to COX-2 inhibitor treatment, Biochemical and Biophysical Research Communications, vol.332, issue.3, 2005. ,
DOI : 10.1016/j.bbrc.2005.05.025
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl)piperidines and structurally related compounds, Journal of Medicinal Chemistry, vol.32, issue.1, 1989. ,
DOI : 10.1021/jm00121a022
Further development and validation of empirical scoring functions for structure-based binding affinity prediction, 2002. ,
Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib:?? New Pharmacological Opportunities Due to Related Binding Site Recognition, Journal of Medicinal Chemistry, vol.47, issue.3, 2004. ,
DOI : 10.1021/jm030912m
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro models, 2000. ,
Chromium (VI) oxide catalysed oxidation of sulfides to sulfones with periodic acid, 2003. ,
Synthesis of some 5-substituted indoles, Heterocycles, vol.34, pp.1169-1175, 1992. ,
Cyclooxygenases in cancer: progress and perspective, Cancer Letters, vol.215, issue.1, pp.1-20, 2004. ,
DOI : 10.1016/j.canlet.2004.06.014
Synthesis of beta-and gamma-carbolines by the palladium-catalyzed iminoannulation of internal alkynes, 2001. ,
Lipoxygenase Pathways in Atherogenesis, Trends in Cardiovascular Medicine, vol.14, issue.5, pp.191-195, 2004. ,
DOI : 10.1016/j.tcm.2004.04.003
Efficient syntheses of 2-(3???,5???-difluorophenyl)-3-(4???-methylsulfonylphenyl)cyclopent-2-enone, a potent COX-2 inhibitor, Tetrahedron, vol.55, issue.19, pp.6001-6018, 1999. ,
DOI : 10.1016/S0040-4020(99)00274-4
Synthesis of Aryl Sulfones via L-Proline-Promoted CuI-Catalyzed Coupling Reaction of Aryl Halides with Sulfinic Acid Salts., ChemInform, vol.70, issue.34, 2005. ,
DOI : 10.1002/chin.200534112